1-Hexylcarbamoyl-5-fluorouracil + cyclophosphamide + tamoxifen versus CMF + tamoxifen in women with lymph node-positive breast cancer after primary surgery: A randomized controlled trial

Oncology Reports

Volumn 12, Issue 4, 2004, Pages 797-803

  Tominaga, Takeshi ^a   Kimura, Morihiko ^b   Asaga, Taro ^c   Yoshida, Minoru ^d   Awane, Hiroharu ^e   Koyama, Hiroki ^f   Takatsuka, Yuichi ^g   Mitsuyama, Syosyu ^h   Ikeda, Tadashi ⁱ   Ogita, Masami ^j   Aoyama, Hideaki ^k   Sano, Muneaki ^l   Abe, Rikiya ^m   Nishi, Tsunehiro ⁿ   Wada, Tomio ^o   Danno, Makoto ^p   Toi, Masakazu ^q   Takashima, Shigemitsu ^r  

^a SHOWA UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b Gunma Cancer Center   (Japan)

^c KANAGAWA CANCER CENTER   (Japan)

^d AICHI CANCER CENTER HOSPITAL   (Japan)

^e OSAKA RED CROSS HOSPITAL   (Japan)

^f OSAKA MEDICAL CENTER FOR CANCER AND CARDIOVASCULAR DISEASES   (Japan)

^g KANSAI ROSAI HOSPITAL   (Japan)

^h KITAKYUSHU MUNICIPAL MEDICAL CENTER   (Japan)

ⁱ KEIO UNIVERSITY   (Japan)

^j National Sapporo Hospital   (Japan)

^k NATIONAL HOSPITAL ORGANIZATION NAGOYA MEDICAL CENTER   (Japan)

^l Niigata Cancer Center   (Japan)

^m FUKUSHIMA MEDICAL UNIVERSITY   (Japan)

ⁿ MITSUI MEMORIAL HOSPITAL   (Japan)

^o KINKI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^p Department of Blood Purification Sangenjaya Hospital   (Japan)

^q TOKYO METROPOLITAN KOMAGOME HOSPITAL   (Japan)

^r NATIONAL HOSPITAL ORGANIZATION SHIKOKU CANCER CENTER   (Japan)

more..

Author keywords

Adjuvant therapy; Breast cancer; CMF; HCFU

Indexed keywords

1-HEXYLCARBAMOYL-5-FLUOROURACIL; ANTINEOPLASTIC AGENT; CARMOFUR; CMF REGIMEN; CYCLOPHOSPHAMIDE; DRUG DERIVATIVE; FLUOROURACIL; METHOTREXATE; TAMOXIFEN;

ADJUVANT CHEMOTHERAPY; ADULT; AGED; ARTICLE; BREAST TUMOR; CANCER INVASION; CANCER STAGING; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE FREE SURVIVAL; FEMALE; HUMAN; LYMPH NODE; LYMPH NODE METASTASIS; MIDDLE AGED; MULTICENTER STUDY; PAGET NIPPLE DISEASE; PATHOLOGY; RANDOMIZED CONTROLLED TRIAL; SURVIVAL RATE;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; CARCINOMA, DUCTAL; CHEMOTHERAPY, ADJUVANT; CYCLOPHOSPHAMIDE; DISEASE-FREE SURVIVAL; FEMALE; FLUOROURACIL; HUMANS; LYMPH NODES; LYMPHATIC METASTASIS; METHOTREXATE; MIDDLE AGED; NEOPLASM INVASIVENESS; NEOPLASM STAGING; SURVIVAL RATE; TAMOXIFEN;

EID: 16644367524     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or.12.4.797     Document Type: Article

References (30)

1. Fisher B, Carbone P, Economou SG, et al: 1-Phenylalanine mustard (L-PAM) in the management of primary breast cancer: a report of early findings. N Engl J Med 292: 117-122, 1975.
2. Early Breast Cancer Trialists' Collaborative Group: Tamoxifen for early breast cancer: an overview for the randomized trials. Lancet 351: 1451-1467, 1998.
3. Early Breast Cancer Trialists' Collaborative Group: Polychemotherapy for early breast cancer: an overview for the randomized trials. Lancet 352: 930-942, 1998.
4. Goldhirsch A, Wood WC, Gelber RD, et al: Meeting highlights: update international expert consensus on the primary therapy of breast cancer. J Clin Oncol 21: 3357-3365, 2003. (Pubitemid 46606270)
5. Bonadonna G, Brusamolino E, Valagussa P, et al: Combination chemotherapy as an adjuvant treatment in operable breast cancer. N Engl J Med 294: 405-410, 1976.
6. Tancini G, Bonadonna G, Valagussa P, et al: Adjuvant CMF in breast cancer: comparative 5-year results of 12 versus 6 cycles. J Clin Oncol 1: 2-10, 1983. (Pubitemid 13066135)
7. Levine MN, Bramwell VH, Pritchard KI, et al: Randomized trial of intensive cyclophosphamide, epirubicin and fluorouracil chemotherapy compared with cyclophosphamide, methotrexate and fluorouracil in premenopausal women with node-positive breast cancer. National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 16: 2651-2658, 1998. (Pubitemid 28363028)
8. Piccart MJ, Di Leo A, Beauduin M, et al: Phase III trial comparing two dose levels of epirubicin combined with cyclophosphamide, methotrexate and fluorouracil in node-positive breast cancer. J Clin Oncol 19: 3103-3110, 2001. (Pubitemid 32565448)
9. Coomber RC, Bliss JM, Wils J, et al: Adjuvant cyclophosphamide, methotrexate and fluorouracil versus fluorouracil, epirubicin and cyclophosphamide chemotherapy in premenopausal women with axillary node-positive operable breast cancer: results of a randomized trial. The International Collaborative Cancer Group. J Clin Oncol 14: 35-45, 1996.
10. Nomura Y, Tominaga T, Adachi I, et al: Clinical evaluation of cyclophosphamide, methotrexate and 5-fluorouracil (CMF) on advanced recurrent breast cancer. Gan To Kagaku Ryoho 21: 1949-1956, 1994. (Pubitemid 24314787)
11. HCFU Clinical Study Group: Absorption and excretion of a new oral antitumor drug, 1-hexylcarbamoyl-5-fluorouracil (HCFU), in cancer patients. Jpn J Clin Oncol 10: 83-92, 1980.
12. Miyauchi M, Yamamoto N, Matsumoto M, et al: Comparative clinical study on 5-FU concentrations for oral HCFU and i.v. 5-FU. Gan To Kagaku Ryoho 27: 1011-1014, 2000.
13. Koyama Y, Cooperative Study Group of HCFU: Phase II study of a new fluorinated pyrimidine, 1-hexylcarbamoyl-5-fluorouracil (HCFU). Jpn J Cancer Chemother 7: 1181-1190, 1980. (Pubitemid 11249471)
14. Tominaga T, Sano M, Kimura, M, et al: Postoperative chemoendocrine therapy for women with node-positive stage II breast cancer with combined cyclophosphamide, tamoxifen and 1-hexyl-carbamoyl-5-fluorouracil. Eur J Surg 187: 598-604, 2001. (Pubitemid 32977185)
15. Sugimachi K, Maehara Y, Ogawa M, et al: Postoperative chemotherapy for colorectal cancer by combining 5-fluorouracil infusion and 1-hexylcarbamoyl-5- fluorouracil administration after curative resection. Cancer 77: 36-43, 1996.
16. Ito K, Yamaguchi A, Miura K, et al: Prospective adjuvant therapy with mitomycin C and carmofur (HCFU) for colorectal cancer, 10-year follow-up: Tokai HCFU Study Group (first study for colorectal cancer). J Surg Oncol 62: 4-9, 1996. (Pubitemid 26134524)
17. Ito K, Yamaguchi A, Miura K, et al: Oral adjuvant chemotherapy with carmofur (HCFU) for colorectal cancer; five-year follow-up. Tokai HCFU Study Group (third study on colorectal cancer). J Surg Oncol 63: 107-111, 1996. (Pubitemid 26357917)
18. Sakamoto J, Kodaira S, Ohashi Y, et al: An individual patients data meta-analysis of long supported adjuvant chemotherapy with oral carmofur in patients with curatively resected colorectal cancer. Oncol Rep 8: 697-703, 2001. (Pubitemid 33758479)
19. Taves DR: Minimization: a new method of assigning patients to treatment and control groups. Clin Pharmacol Ther 15: 443-453, 1974.
20. Kaplan EL and Meier P: Non-parametric estimation from incomplete observations. J Am Stat Assoc 53: 457-481, 1958.
21. Falkson HC, Gary R, Wolberg WH, et al: Adjuvant trial of 12 cycles of CMFPT followed by observation or continuous tamoxifen versus four cycles of CMFPT in postmenopausal women with breast cancer: an Eastern Cooperation Oncology Group phase III study. J Clin Oncol 8: 599-607, 1990. (Pubitemid 20127242)
22. Ito K, Kato T, Takagi H, et al: Optimum duration of oral adjuvant chemotherapy of HCFU for colorectal cancer. Review of 5-year follow-up. Anticancer Res 20: 4681-4686, 2000. (Pubitemid 32127710)
23. Kasumi F, Yoshimoto M, Abe O, et al: Meta-analysis of five studies on tegafur plus uracil (UFT) as post-operative adjuvant chemotherapy for breast cancer. Oncology 64: 146-153, 2003. (Pubitemid 36173380)
24. Tominaga T, Koyama H, Toge T, et al: Randomized controlled trial comparing oral doxifluridine plus oral cyclophosphamide with doxifluridine alone in women with node-positive breast cancer after primary surgery. J Clin Oncol 21: 991-998, 2003. (Pubitemid 46594126)
25. Blum JL, Jones SE, Buzdar AU, et al: Multicenter phase II study of capecitabine in paclitaxel-refractory metastatic breast cancer. J Clin Oncol 17: 485-493, 1999. (Pubitemid 29075232)
26. O'Shaughnessy JA, Blum J, Moiseyenko V, et al: Randomized, open-label, phase II trial capecitabine (Xeloda) vs. a reference arm of intravenous CMF (cyclophosphamide, methotrexate and 5-fluorouracil) as first-line therapy for advanced/metastatic breast cancer. Ann Oncol 12: 1247-1254, 2001. (Pubitemid 32994752)
27. O'Shaughnessy J, Miles D, Vekelja S, et al: Superior survival with capecitabine plus docetaxel combination therapy in anthracycline-pretreated patients with advanced breast cancer: Phase III trial results. J Clin Oncol 20: 2812-2823, 2002. (Pubitemid 34651510)
28. Douillard JY, Hoff PM, Skillings JR, et al: Multicenter phase III study of uracil/tegafur and oral leucovorin versus fluorouracil and leucovorin in patients with previously untreated metastatic colorectal cancer. J Clin Oncol 20: 3605-3616, 2002. (Pubitemid 34983220)
29. Carmichael J, Popiela T, Radstone D, et al: Randomized comparative study of tegafur/uracil and oral leucovorin versus parenteral fluorouracil and leucovorin in patients with previously untreated metastatic colorectal cancer. J Clin Oncol 20: 3617-3627, 2002. (Pubitemid 34983221)
30. Watanabe T: Phase III randomized comparison of postoperative adjuvant chemotherapy with 2-year oral UFT (uracil/tegafur) versus six-cycle CMF (cyclophosphamide/methotrexate/5-fluorouracil) in high-risk node-negative breast cancer patients. Jpn J Clin Oncol 28: 77-80, 1998.